Sullens

Researchers are evaluating a high-dose, high-intensity (HDHI) neurorehabilitation program designed to improve functional outcomes for adults who have experienced a stroke. This study is part of the SwissNeuroRehab initiative, which aims to develop and assess innovative, technology-supported neurorehabilitation methods across various care settings in Switzerland. The focus is on understanding the feasibility and clinical impact of this HDHI therapy pathway in real-world inpatient, outpatient, and home environments for people in subacute and chronic stages after stroke. Participants will take part in a structured HDHI therapy program using CE-marked digital therapeutic devices such as MindMotion GO and Izar. The intervention is tailored to individual motor rehabilitation needs and delivered during inpatient rehabilitation lasting 4 to 6 weeks and/or home-based outpatient care lasting 8 to 12 weeks. Participants are expected to engage in about one hour of active, technology-supported training per day, five days a week, in addition to their standard rehabilitation care. Clinical teams trained in the HDHI protocol will supervise the therapy, providing ongoing support and monitoring progress throughout the treatment. During the study, participants will be assessed at baseline, discharge, and follow-up timepoints up to 12 to 15 months after enrollment. Researchers will collect standardized clinical assessments, patient-reported outcomes, rehabilitation records, and socioeconomic data. The main outcomes measured include adherence to the training schedule and participants' satisfaction with the program. Secondary outcomes explore preliminary clinical and functional changes and socioeconomic impacts. The total study duration allows for detailed monitoring of the intervention's feasibility and initial clinical effects across multiple Swiss rehabilitation centers.